Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
71 results about "Gonadal hormones" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Gonadal hormones: Hormones produced by the GONADS, including both steroid and peptide hormones. The major steroid hormones include ESTRADIOL and PROGESTERONE from the OVARY, and TESTOSTERONE from the TESTIS. The major peptide hormones include ACTIVINS and INHIBINS.
Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders
A compound is provided that has the formula NH2CH2CH2CHR1C(O)N—R (I) where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.
Owner:MILLER LANDON C G
Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
InactiveUS7151084B2Nervous disorderPeptide/protein ingredientsMembrane TransportersPancreatic hormone
A complex is provided for the treatment of neurogenic conditions having the formula:where R1 isM is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium(II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium(II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium(II):transporter ligand.
Owner:MILLER LANDON C G
Process for the synchronization of ovulation for timed breeding without heat detection
ActiveUS20050130894A1Efficient methodAnimal reproductionPeptide/protein ingredientsOvulation timesSingle injection
A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.
Owner:THORN BIOSCI
Condensed-ring thiophene derivatives, their production and use
A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a contraceptive of male or female, as an ovulation-inducing agent of female; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; is useful as modulating estrous cycles in animals in the field of animal husbandry, as an agent fro improving the quality of edible meat or promoting the growth of animals; is useful as an agent of spawning promotion in fish.
Owner:TAKEDA PHARMA CO LTD
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
Owner:WYETH
Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders
A compound of the formulawhere R1 is H, C1–C4 alkyl and OH; R2 in is H, C1–C4 alkyl and OH; R3 is H and C1–C4 alkyl; R4 is H and C1–C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2–C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.
Owner:MILLER LANDON C G
Sperm and ovum health beverage
InactiveCN101589814ASimple processLow costMilk preparationFood preparationSexual functionPalpitations
The invention relates to a sperm and ovum health beverage which comprises fulvic acid, gene vitality element, plant extract, fungus polysaccharide, vitamin, hydroxycitric acid (HCA), soluble dietary fiber, L-arginine, L-carnitine, zinc gluconate, calcium lactate, sweetening agent, milk, coffee and purified water. The invention has simple technology, low cost and complete product nutrition and contains rich natural polypeptide, polysaccharide, amino acid and vitamin and various trace elements. All components interact to promote blood circulation and sex hormone secretion so as to achieve the functions of promoting the growth of sperms and ovums, improving the quality and the vitality of the sperms and the ovums and improving the sexual function. The sperm and ovum health beverage has the good improving effect on ED symptoms including renal dysfunction, working strain, heavy spirit pressure, bradypsychia, palpitation, stomachache, weak waist and knee, sexual dysfunction, and the like. As a pure natural preparation, the sperm and ovum health beverage has no poison and side effect and adverse reaction.
Owner:程礼华
Gonadal function improving agents
ActiveUS20060287227A1Reduce releaseReduces of production of testosteroneOrganic active ingredientsPeptide/protein ingredientsOvulation timesDepressant
Owner:TAKEDA PHARMA CO LTD
Fusion protein capable of inducing and activating cancer targeting T-cells as well as preparation method and application of the fusion protein
ActiveCN102391377ACancer targetingGood killing effectBacteriaPeptide/protein ingredientsCancer targetingVascular endothelium
The invention discloses a fusion protein capable of inducing and activating cancer targeting T-cells as well as a preparation method and application of the fusion protein. The fusion protein contains peptide acting with cancer cells as well as costimulatory molecules B7.1, wherein the peptide acting with the cancer cells is selected from a transforming growth factor-alpha, an epidermal growth factor, a vascular endothelial growth factor, gonadotropinreleasing hormone or gastrin-releasing peptide. The fusion protein has a targeting function; the fusion protein can act with VEGFR, EGFR, GnRH-R, or GRP-R respectively on one hand and interact with corresponding receptors CD28 and CTLA-4 expressed on the T-cells, therefore the targeting of the T-cells is positioned at the periphery of the cancer cells greatly expressing VEGFR, EGFR, GnRH-R, or GRP-R. Proven by experiments, the fusion protein can restrain the growth of tumors and cause cancer cells to apoptosis.
Owner:孙嘉琳 +1
Method for preparing a sterile transgenic fish
InactiveUS20050257281A1Easy to operateSolve the real problemPisciculture and aquariaFermentationCommon carpGonadotropin-releasing hormone-III
The present application disclosed a method for preparing a sterile transgenic fish, comprising constructing antisense RNA expression vector of salmon-type gonadotropin-releasing hormone, introducing the recombinant DNA fragment into carp oosperm by microinjection, and screening the sterile transgenic fish by Polymerase Chain Reaction and radioimmunoassay, wherein the expression vector comprising a promoter of carp beta actin (β-actin) gene, a complementary DNA fragment of antisense salmon-type gonadotropin-releasing hormone (sGnRH) gene from carp with 323 bp as a target gene comprising sGnRH decapeptide, the coding region of gonadotropin-releasing hormone associated peptide and 3′ non-coding sequence, and 3′ flanking sequence of grass carp growth hormone gene as a stop sequence. The method of the present invention is easy and convenient for operation which provides a basis for providing a technical platform of general applicability for solving the hereditary and ecological safety problems of transgenic fishes.
Owner:INST OF AQUATIC LIFE ACAD SINICA
Expression of properly folded and soluble extracellular domain of a gonadotropin receptor
InactiveUS20020128190A1Reduce productionEasy to producePeptide/protein ingredientsAntibody mimetics/scaffoldsPregnancyGonadotropin receptor
This invention provides a nucleic acid which encodes a soluble polypeptide which comprises the extracellular domain of a gonadotropin receptor and thioredoxin, wherein the soluble polypeptide is capable of binding to the gonadotropin. This invention also provides the polypeptides encoded by these nucleic acids and methods to produce the polypeptides. This invention also provides methods of preventing or terminating pregnancy, preventing or treating cancer, and decreasing androgen and estrogen production.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
LHRH antagonist with low-histamine releasing function
InactiveCN101037472AGood LHRH antagonistic activityLow histamine release side effectsPeptide/protein ingredientsBiological material analysisLhrh antagonistLhrh receptor
The invention relates to decapeptide derivative which has LHRH receptor antagonism activity, an effect of inhibiting pituitary to excrete gonadotrophic hormone, an effect of inhibiting the gonad to excrete steroid hormone and has a lower histamine releasing effect, its producing method, the drug combination and its drug applications for treating the sex hormone correlated disease such as prostatecancer and the disease correlated to the anti-histamine or reducing histamine release.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Pig oocyte in-vitro maturation culture solution and preparation method and application thereof
ActiveCN110760473AImprove the quality of external ripeningIncreased Diffusion IndexCulture processCell culture active agentsPenicillinPhysiology
The invention discloses a pig oocyte in-vitro maturation culture solution and a preparation method and application thereof, and belongs to the technical field of oocyte in-vitro maturation culture. The problems of low in-vitro maturation rate and development rate of porcine oocytes currently are solved. The pig oocyte in-vitro maturation culture solution is prepared from a basal culture solution TCM-199, penicillin, streptomycin, NaHCO3, 4-hydroxyethylpiperazine ethane sulfonic acid, polyvinyl alcohol, sodium pyruvate, insulin, cysteine, epidermal growth factor, porcine follicular fluid, pregnant mare serum gonadotropin, human chorionic gonadotropin and tannic acid. According to the pig oocyte in vitro maturation culture solution, the oocyte in-vitro maturation quality, the cumulus cell diffusion index, the parthenogenetic embryo blastocyst rate and blastocyst total cell number, and the in-vitro fertilization embryo cleavage rate, blastocyst rate and blastocyst total cell number can beimproved.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
Method of improving ovulation induction using an androgen such as dehydroepiandrosterone
InactiveUS20060089308A1Maximize ovulation inductionBiocideOrganic active ingredientsLeuprorelinHuman Females
A method of preconditioning ovulation induction in a human female comprises of administering an androgen, for example, DHEA, for at least about four consecutive months. DHEA may be administered along with high dose gonadotrophins in ovulation induction treatments. Moreover, DHEA may be administered with follicle stimulating hormone, human menopausal gonadotrophin, norethindrone acetate, leuprolide acetate, and human chorionic gonadotrophin in ovulation induction treatments.
Owner:AMERICAN INFERTILITY OF NEW YORK
LHRH antagonist with long-acting low-histamine release side effect
The invention relates to a decapeptide derivative with LHRH receptor antagonism activity and actions of restricting a pituitarium to secrete gonadotrophins and restricting a gonad to secrete steroid hormones, a preparation method thereof, a medicine composition containing the decapeptide derivative and the application of the medicine composition on treating prostatic cancer, endometrial cancer, interrelated sex hormone dependence diseases relative to reproduction, contraception, and the like.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Gonadal function improving agents
InactiveUS20110052563A1Reduce productionReduce releaseOrganic active ingredientsPeptide/protein ingredientsGonad functionReceptor
Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing / treating sterility, hormone-sensitive cancers, endometriosis, etc. Metastin and its receptors are useful for screening for these pharmaceuticals.
Owner:TAKEDA PHARMA CO LTD
Antagonist of luteinizing hormone releasing hormone (LHRH) containing hydantoin structure
The invention relates to an antagonist of luteinizing hormone releasing hormone (LHRH) containing a hydantoin structure, and particularly relates to a decapeptide derivative which has LHRH receptor antagonism activity, can inhibit hypophysis from secreting gonadotropin and inhibit sexual gland from secreting steroid hormone and is shown in the formula (I): R-Xaa<3>-Ser-Saa <5>-Xaa<6>-Xaa<7>-Xaa<8>-Pro-D-Ala-B, wherein the definition of each symbol is in the specification. The invention also relates to a preparation method of compounds as shown in the formula (1), a pharmaceutical composition containing the compounds and applications of the compounds in preparing medicaments.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Preparation method of nuisance-free environmentally-friendly pest sticker
InactiveCN105647465AIncrease stickinessReduce pollutionNon-macromolecular adhesive additivesWax adhesivesGonadal hormonesNatural state
The invention discloses a preparation method of a nuisance-free environmentally-friendly pest sticker, and belongs to the technical field of pest stickers. The preparation method of the nuisance-free environmentally-friendly pest sticker adopting natural gum secreted by peaches as the base of the pest sticker comprises the following steps: mixing the natural gum with sodium carbonate, mixing and reacting at a high temperature to increase the viscosity, reacting the obtained product with Vaseline and polybutadiene to form an pest sticker matrix, extracting gonadal hormones and other attractive hormones in pests, and mixing the gonadal hormones and other attractive hormones with the obtained pest sticker to obtain the nuisance-free environmentally-friendly pest sticker. Instances prove that the pest sticker prepared in the invention has the advantages of nontoxic and tasteless property, maintenance of the viscosity in natural state for 1-2 years, and realization of environment pollution due to self degradation after being used, and has a prevention and control effect reaching 85% or above.
Owner:CHANGZHOU SIYU ENVIRONMENTAL PROTECTION MATERIAL SCI & TECH
Porcine oocyte in-vitro maturation culture solution as well as preparation method and application thereof
ActiveCN110684723AReducing ROS levelsIncreased Diffusion IndexCell culture active agentsGerm cellsPolyvinyl alcoholPancreatic hormone
The invention discloses a porcine oocyte in-vitro maturation culture solution as well as a preparation method and application thereof and belongs to the technical field of oocyte in-vitro maturation culture. In order to solve the problems of low porcine oocyte in-vitro maturation rate and development rate at present, the invention provides the porcine oocyte in-vitro maturation culture solution aswell as the preparation method and application thereof. The culture solution comprises a base culture solution TCM-199, penicillin, streptomycin, NaHCO3, 4-hydroxyethylpiperazine ethane sulfonic acid, polyvinyl alcohol, sodium pyruvate, insulin, cysteine, an epidermal growth factor, a porcine follicular fluid, pregnant mare serum gonadotropin, human chorionic gonadotropin and ramelteon. The culture solution can increase the oocyte in-vitro maturation quality, the cumulus cell diffusion index, the glutathione level, the parthenogenetic embryo blastocyst rate and blastocyst total cell number, the in-vitro fertilization embryo cleavage rate, the blastocyst rate and blastocyst total cell number and decrease the ROS level of oocytes.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
Agonists and antagonists of gonadotropin-releasing hormone-2, and use thereof
InactiveUS7285528B2Peptide/protein ingredientsLuteinising hormone-releasing hormoneDiseaseCancer cell
The present invention relates to agonists and antagonists of gonadotropin-releasing hormone-2 (GnRH-2), which regulates the activity of GnRH-2 by specifically binding to GnRH-2 receptors, and uses thereof. The pharmaceutical compositions comprising the GnRH-2 agonists and antagonists according to the present invention are useful for the treatment of reproductive physiology diseases and steroid-related cancer cells because they specifically bind to the GnRH-2 receptors, and they are also usefully applicable to the raising industry of non-mammalian animals, i.e., birds and fish.
Owner:NEUROGENEX CO LTD
PVC (polyvinyl chloride) hose
ActiveCN105694280AGuaranteed cleanlinessImprove heat resistanceFlexible pipesGonadal hormonesPlasticizer
The invention relates to a PVC (polyvinyl chloride) hose which is prepared from the invention relates to a PVC (polyvinyl chloride) hose which is prepared from 100 parts of SG-3 PVC resin, 48-56 parts of non-phthalic plasticizer, 0.9-1.3 parts of Ca / Zn composite stabilizer, 0.1 part of stearic acid, 0-0.02 part of whitener, 0-0.02 part of blue ultramarine, 0-1.5 parts of ACR resin and 0-1.5 parts of titanium white. The PVC hose can not cause environmental pollution since no phthalic plasticizer participates; and the disorder of gonadal hormones in the human body causes disorder of sexuality of the human body.
Owner:TAIZHOU FENGYUAN SANITARY CO LTD
Agents and methods for modulating interactions between gonadotropin hormones and receptors
InactiveUS20050142135A1Antibody ingredientsImmunoglobulins against hormonesGonadotropin receptorEphA Receptors
The present invention relates to agents and methods for the modulation of gonadotropin hormones and their receptors, including methods of treating gonadotropin disorders and conditions and screening and development of therapies. Specifically, the present invention relates to modulation of gonadotropin hormones through the inhibition of activity of exoloop 1, exoloop 2 and exoloop 3 of gonadotropin receptors.
Owner:UNIV OF KENTUCKY RES FOUND
Application of clomifene citrate to anti-mycobacterium tuberculosis medicines
InactiveCN110354108AHas an anti-tuberculosis effectGood development valueAntibacterial agentsOrganic active ingredientsClomifene citrateOvarian follicle
The invention relates to application of clomifene citrate to anti-mycobacterium tuberculosis medicines. Clomifene citrate has estrogenic and antiestrogenic properties that appear to prevent the release of gonadotropins, follicle-stimulating hormone and luteinizing hormone, thus leading to follicular development and maturation, ovulation and subsequent corpus luteum development and function and then resulting in pregnancy. It is found through researches that the clomifene citrate has an antitubercular effect and has good development value. The application of the clomifene citrate to anti-mycobacterium tuberculosis medicines and the obvious anti-mycobacterium tuberculosis effect of the clomifene citrate are disclosed for the first time.
Owner:SHENZHEN UNIV
Extraction and culture method of mouse ovarian granular cells
PendingCN113462637AHigh yieldSimple and fast operationCell dissociation methodsArtificial cell constructsIntraperitoneal routeGranular cell
The invention belongs to a cell biology technology, and particularly relates to an extraction and culture method of mouse ovarian granular cells. According to the technical scheme, the method comprises the following specific steps: (1) injecting pregnant mare serum gonadotropin PMSG into the abdominal cavity of a female mouse; (2) killing the mouse by using a cervical vertebra dislocation method, separating the ovary of the mouse, cleaning with PBS (Phosphate Buffer Solution), and removing a fat envelope around the mouse under a microscope; (3) puncturing follicles in the mixed operation solution by using a syringe needle to release granular cells and oocytes, filtering by using a screen, centrifuging the filtrate, and discarding the supernatant; and (4) mixing the complete culture medium, resuspending the cells, precipitating and inoculating, wherein the operation liquid includes DME / F-12:1(1X), 3% of fetal calf serum, 2% of mycillin mixed liquid and 2% of mycoplasma scavenger. Furthermore, the mouse is an immature female mouse which is 3 weeks old and 10-13g in weight, the injection amount of the PMSG is 5-10IU, the injection method is intraperitoneal injection, the injection amount of the PMSG is preferably 8IU, and the time for killing the mouse after cervical vertebra dislocation is 46-48h after injection. The mechanical method provided by the invention is simple and convenient to operate and short in time consumption, and the obtained ovarian granular cells are high in yield.
Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
Ten-medicine Xiang Lu capsule, preparation method thereof and ginsenoside content analysis method
InactiveCN110917313AReduce the numberReduce usageComponent separationUnknown materialsFormularyEstradiolum
The invention discloses a ten-medicine Xiang Lu, a preparation method thereof and a ginsenoside content analysis method, and belongs to the technical field of traditional Chinese medicine formulas. The capsule gives full play to the values of the traditional Chinese medicines, has the effects of soothing liver-qi stagnation, softening hardness to dissipate stagnation and the like, the pharmacodynamic material basis of ginseng is ginsenoside which has an adjusting effect on the neuroendocrine function of the pituitary-gonad axis and can excite the pituitary to secrete gonadotropin, promote biosynthesis of DNA and protein synthesis related zymoprotein and increase the gonad activity. Through the two-way regulation effect on the pituitary-gonad axis, the positive and negative feedback functions of neuroendocrine are balanced so as to achieve the purpose of reducing estradiol which is abnormally increased, and mammary gland cell proliferation controlled by ovarian hormone is inhibited; andinternal components of traditional Chinese medicines are selected as internal standards in a quantitative analysis of multiple components by single marker, and the content of the to-be-detected components is calculated by measuring relative correction factors (RCF) between the internal standards and other to-be-detected components, so that the use amount of reference substances is reduced, and the cost is saved.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE
Porcine oocyte in-vitro maturation system containing butoxylic acid and application of porcine oocyte in-vitro maturation system
ActiveCN113174366AImprove developmental efficiencyReduce apoptosis rateCulture processCell culture active agentsGonadal hormonesMolecular biology
The invention discloses a porcine oocyte in-vitro maturation system containing butoxylic acid and an application of the porcine oocyte in-vitro maturation system. A culture solution is prepared from a basic culture solution TCM-199, cysteine, penicillin, streptomycin, an insulin-like growth factor, an epidermal growth factor, fetal calf serum, pig follicle fluid, NaHCO3, pregnant mare serum gonadotropin, human chorionic gonadotropin and Bufexamac, and the apoptosis rate of in-vitro development of oocytes can be reduced; and the first polar body discharge rate, the parthenogenetic embryo cleavage rate, the blastocyst rate, the blastocyst total cell number, the in-vitro fertilization embryo cleavage rate, the blastocyst rate and the blastocyst total cell number are improved.
Owner:GUANGXI ZHUANG AUTONOMOUS REGION INST OF ANIMAL HUSBANDRY
Method for analyzing content of ginsenoside in ten-ingredient Xiangdeer capsule
ActiveCN113866288AReduce the numberReduce usageComponent separationAgainst vector-borne diseasesFormularyPhysiology
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE
Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
Owner:AGOURON PHARMA INC
Crystal forms and amorphous solid of relugolix compound and preparation method of crystal forms and amorphous solid
The invention discloses crystal forms and an amorphous form of a gonadotropin releasing hormone (GnRH) receptor antagonist drug relugolix and a preparation method of the crystal forms and the amorphous form, and relates to the field of chemical medicines. The crystal forms and the amorphous form provided by the invention have good stability, and have great significance for the purification processof active pharmaceutical ingredients and the preparation process of drugs.
Owner:SUZHOU PENGXU PHARM TECH CO LTD +1
GNRH (gonadotropin-releasing hormone) peptide variants
The inventors have discovered that substituting amino acid residues at positions 5 and / or 7 and / or 8 of the GnRH I (gonadotropin-releasing hormone) peptide sequence, and particularly removal of the arginine residue at position 8, results in elevated antiproliferative activitey. Furthermore, the introduction of certain D-amino acid residues at position 6 of the GnRH II peptide sequence results in elevated antiproliferative activity. This surprising discovery provides potent and selective agents for use in treating antiproliferative disorders, such as cancer.
Owner:MEDICAL RESEARCH COUNCIL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com